Allogeneic CAR T-Cell Patent Landscape Report 2026 Edition

Patent Landscape Report Coverage

The global allogeneic CAR T-cell patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for global allogeneic CAR T-cell include patent distribution by time, geographical coverage, top IP player profiles, technological segmentation, and patent valuation.

A thorough examination of the patent portfolios of key players, covering aspects such as the number of patents, types of technologies patented, and trends over time. A detailed description of the companies granted with patents, analysis of the distribution of patents geographically, and information on key regions where patent filings are concentrated. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within allogeneic CAR T-Cell technologies.

For instance, CRISPR/Cas9 gene editing technology permits exact T cell modification for the need of inserting the CAR gene and conditionally editing other genes to increase safety, improve persistence or lessen immunological rejection.

Global Allogeneic CAR-T Cell Patent Market Outlook

• Diseases like cancer and graft-versus-host disease (GvHD) require elimination of T-cell receptors (TCRs) using gene editing techniques, thereby fueling the need for sophisticated gene therapy methods is augmenting the market size and growth rate.

• Universities and healthcare companies are investing effectiveness and specificity of CAR T-cells against cancer cells, which is helping in the growth of medical treatment options in the healthcare sector.

• The pharmaceutical and biopharmaceutical companies and research institutions are actively investing the allogeneic CAR T-cells to boost the immune system response against foreign unhealthy cells.

What are Allogeneic CAR T-Cells?

Allogeneic CAR T-Cell (chimeric antigen receptor) therapy is a state-of-the-art cancer treatment that uses T cells from healthy donors. Thanks to genetic engineering, these T-cells express receptors that specifically target antigens in cancer cells. When compared to autologous CAR-T therapy (which makes use of the patient’s cells), this over-the-counter therapy enables quicker and more extensive treatment. Avoiding graft-versus-host disease (GvHD), which is commonly treated with gene editing, is one of the major.

Allogeneic CAR T-cell continues to evolve, driven by decreasing the cost of therapy making it more affordable and accessible. Its ability to deliver effective therapeutic results in combination with other therapies against cancer and other immune diseases, which is a driving factor for the market in forecasted period.

Global Allogeneic CAR-T Cell Industry Growth Drivers

Technical Advancements and Product Launches are Expected to Augment the Market Growth

Universal donor CAR-T cells are engineered from healthy donors and designed to be used across multiple patients, providing an off-the-shelf solution. Allogeneic CAR T-cell treatment options are getting advanced by the research and development of market leaders to treat diseases like cancer.

For instance, in January 2023, a well-known company, Allogene Therapeutic’s ALLO-501, an Allogeneic CAR T-cell therapy targeting CD19 (a protein present on the surface of B-cell tumors) showed promising results in its phase-1 clinical trial when used for the treatment of non-Hodgkin lymphoma. The ability to develop a ready-to-use therapy lowers production time and costs significantly in comparison to patient-specific (autologous) CAR-T treatments, increasing accessibility and scalability of the treatment.

Gene Editing Technologies to Enhance the Efficacy and Safety is Expected to Propel the Allogeneic CAR-T Cell Industry Growth

Enhancing the safety and efficacy of allogeneic CAR T-cell therapies requires the application of CRISPR /Cas9 and other gene editing technologies. These technologies enable the precise modification of T-cells to target cancer and eliminate T-cell receptors (TCRs) that cause graft-versus-host disease (GvHD) more efficiently. Consequently, there is a decreased possibility of adverse reactions and safer, more efficient treatments.

Global Allogeneic CAR-T Cell Industry Patent Landscape

The report will cover the following sections in detail:

Breakup by Type

• Stem Cell

• Non-Stem Cell

Breakup by Target Indication

• Acute Lymphoblastic Leukemia

• Diffuse Large B-cell Lymphoma

• Follicular Lymphoma

• Large B-cell Lymphoma

• Mantle Cell Lymphoma

• Others

Breakup by Target Antigen

• CD19

• BCMA

• CD20

• CD19/22

• Others

Allogeneic CAR-T Cell Patent Segmentation Analysis

Allogeneic CAR T-Cell investigations have been conducted with the chosen patent families based on the technology to which they pertain. This patent landscape report features various technologies present in the allogeneic CAR T-Cell market including zinc finger nucleases (ZFN), next-generation sequencing (NGS), clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 and transcription activator-like effector nucleases (TALEN). Next-generation sequencing (NGS) is used in allogeneic CAR-T Cell therapy to perform comprehensive quality control and genetic screening of engineered T-cells. This ensures that the modified T-cells meet all relevant safety and efficacy standards are free of accidental alterations and have the necessary genetic modifications before being infused into patients.

The detailed technological data will be provided for all specified segments classified in this report.

Allogeneic CAR-T Cell Patent Jurisdiction Analysis

Over half of the allogeneic CAR T-Cell patent filings are in the United States, underscoring its role as the global hub for Allogeneic CAR T-cell development. The region has a strong biotech industry, funding ecosystem, and presence of leading CAR-T companies (e.g., Allogene Therapeutics, Precision BioSciences). The FDA’s evolving regulatory framework for cell therapies may also encourage filings. The EU remains a critical secondary market with steady filings, probably targeting Germany, the UK, and France during national phase entry. A significant portion of filings suggest active European interest. Regulatory harmonization through the EPO and access to multiple EU markets make this a valuable region.

Patent Profile of Key Companies

This study includes an analysis of key players in the global allogeneic CAR T-Cell patent landscape, detailing their patent portfolios, patent issuance trends over time, geographic coverage, active patents in various technical segments, and financial analysis. After this patent profile overview, we look at the technological content found in their main patents.

Among the players with allogeneic CAR T-cell patent families, pre-existing new entrants have been identified. These companies can be either established companies or startups developing their first technology in the field.  These innovative companies can become a future key player in healthcare, attracting investments from major corporations.

Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Bristol Mayer Squibb Company

A biopharmaceutical company renowned for developing innovative cancer, cardiovascular, and immunology treatments. BMS is working hard to improve its Allogeneic CAR-T Cell (chimeric antigen receptor) therapy pipeline. The company wants to create off-the-shelf CAR-T cell treatments that will improve accessibility and efficacy for cancer patients by employing cutting-edge gene editing technologies.

Compugen LTD

Leading therapeutic development company focused on mmune-oncology discovery at the clinical stage. This company uses its computational discovery platforms and in-depth understanding of the tumour microenvironment to collaborate with other biopharmaceutical companies on cutting-edge therapies, such as Allogeneic CAR-T cell therapies, to improve cancer treatment. Development of biological drugs and the identification of new drug targets are its two main areas of expertise.

Other players in the market include Artiva Biotherapeutics Inc., Poseida Therapeutics, Inc., Nanjing Beiheng Biological Technology Co., Ltd., and NantCell, Inc., among others.

Reasons to Purchase this Report

Studying the intellectual property (IP) position and strategy of players in the global allogeneic CAR T- cell patent landscape report is crucial for several reasons:

• Competitive Advantage: Revealing the market leaders, potential partners and innovators also make it understandable which companies have important patents in this field of allogeneic CAR-T cell. This helps stakeholders identify the key players that shape the industry and predict future market dynamics.

• Innovation Insights: The patent application represents the ongoing efforts of various companies and organizations. This analysis reveals new technologies and innovations in Allogeneic CAR-T Cell. This helps stakeholders stay aware and alert of the advancements and potential disruptions.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as Allogeneic CAR-T Cell, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

• Legal and Regulatory Compliance: Understanding the intellectual property environment is critical to ensuring compliance with patent laws and regulations. It helps stakeholders navigate license agreements, avoid infringement lawsuits, and effectively use IP assets in a global marketplace.

Key Questions Answered in the Global Allogeneic CAR-T Cell Patent Landscape Report

• What are the key players in the allogeneic CAR-T cell patent landscape?
• What is the technological focus of patents in the allogeneic CAR-T cell industry?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in allogeneic CAR-T cell patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• How do patent strategies impact competitive advantage?
• What are the implications of intellectual property rights in allogeneic CAR-T cells?
• What are the challenges and opportunities in the allogeneic CAR-T cell patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in allogeneic CAR-T cell industry?

Related Reports

Global CAR-T Cell Therapy Market 

Global Gene Therapy Market

Global Cell and Gene Therapy Market

Global Cancer Immunotherapy Market

Global Cancer Cryotherapy Market